人成骨肉瘤細(xì)胞Saos-2

簡要描述：青旗（上海）生物技術(shù)發(fā)展有限公司，總部位于上海浦東新區(qū)，依托本地高校資源，逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺，在標(biāo)準(zhǔn)化細(xì)胞庫建立及細(xì)胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細(xì)胞、細(xì)胞系、ELISA試劑盒、感受態(tài)細(xì)胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶負(fù)責(zé)的態(tài)度，以對科研的高度嚴(yán)謹(jǐn)，以嚴(yán)格的質(zhì)量控制，為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)！

更新時間：2021-05-21

廠商性質(zhì)：生產(chǎn)廠家

瀏覽次數(shù)：490

留言詢價聯(lián)系我們

詳情介紹

品牌	其他品牌	貨號	BFN608006109
規(guī)格	T25培養(yǎng)瓶x1 1.5ml凍存管x2	供貨周期	現(xiàn)貨
主要用途	僅供科研	應(yīng)用領(lǐng)域	醫(yī)療衛(wèi)生,生物產(chǎn)業(yè)

細(xì)胞名稱	人成骨肉瘤細(xì)胞Saos-2
貨物編碼	BFN608006109
產(chǎn)品規(guī)格	T25培養(yǎng)瓶x1	1.5ml凍存管x2
細(xì)胞數(shù)量	1x10^6	1x10^6
保存溫度	37℃	-198℃
運輸方式	常溫保溫運輸	干冰運輸
安全等級	1
用途限制	僅供科研用途

培養(yǎng)體系	DMEM高糖培養(yǎng)基（Hyclone）+10%胎牛血清（Gibco）+1%雙抗（Hyclone）
培養(yǎng)溫度	37℃	二氧化碳濃度	5%
簡介	人成骨肉瘤細(xì)胞Saos-2 細(xì)胞取自高加索人種，女性，11歲。
注釋	Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). From: Memorial Sloan Kettering Cancer Center; New York; USA. Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 771. Doubling time: 48 hours (PubMed=16888811); 45.7 +- 3.3 hours (PubMed=10763916); 35-40 hours (CLS); ~43 hours (DSMZ). Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger). Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: H3K4me1 ChIP-seq epigenome analysis. Omics: SNP array analysis. Omics: Transcriptome analysis.
STR信息	Amelogenin: X CSF1PO: 10 D13S317: 12,13 D16S539: 12,13 D5S818: 12 D7S820: 8,10 TH01: 6,9 TPOX: 8 vWA: 18
參考文獻(xiàn)	PubMed=833871; DOI=10.1093/jnci/58.2.209 Fogh J., Wright W.C., Loveless J.D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58:209-214(1977) PubMed=6935474; DOI=10.1093/jnci/66.2.239 Wright W.C., Daniels W.P., Fogh J. Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis. J. Natl. Cancer Inst. 66:239-247(1981) PubMed=7017212; DOI=10.1093/jnci/66.6.1003 Pollack M.S., Heagney S.D., Livingston P.O., Fogh J. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66:1003-1012(1981) PubMed=3518877; DOI=10.3109/07357908609038260 Fogh J. Human tumor lines for cancer research. Cancer Invest. 4:157-184(1986) PubMed=3040234 Rodan S.B., Imai Y., Thiede M.A., Wesolowski G., Thompson D., Bar-Shavit Z., Shull S., Mann K., Rodan G.A. Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res. 47:4961-4966(1987) PubMed=2823272; DOI=10.1073/pnas.84.21.7716 Masuda H., Miller C., Koeffler H.P., Battifora H., Cline M.J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987) PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D., Lollini P.-L., Picci P., Bertoni F., Baldini N. Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. Hum. Pathol. 27:408-416(1996) PubMed=10763916; DOI=10.1023/A:1006623001465 Jia S.-F., Worth L.L., Kleinerman E.S. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin. Exp. Metastasis 17:501-506(1999) PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4 Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Bocker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C. Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping. Cancer Genet. Cytogenet. 140:145-152(2003) PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809 Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R., Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B., Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G., Gabbert H.E., Poremba C. Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3. Cancer Res. 64:3395-3405(2004) PubMed=15736406 Pautke C., Schieker M., Tischer T., Kolk A., Neth P., Mutschler W., Milz S. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res. 24:3743-3748(2004) PubMed=15939397; DOI=10.1016/j.bbrc.2005.05.097 Hausser H.-J., Brenner R.E. Phenotypic instability of Saos-2 cells in long-term culture. Biochem. Biophys. Res. Commun. 333:216-222(2005) PubMed=16888811; DOI=10.1002/jcb.21073 Moneo V., Serelde B.G., Fominaya J., Leal J.F.M., Blanco-Aparicio C., Romero L., Sanchez-Beato M., Cigudosa J.C., Tercero J.C., Piris M.A., Jimeno J., Carnero A. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J. Cell. Biochem. 100:339-348(2007) PubMed=17354236; DOI=10.1002/ijc.22643 Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G., Myklebost O. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int. J. Cancer 121:199-205(2007) PubMed=17431109; DOI=10.1158/1535-7163.MCT-06-0729 Moneo V., Serelde B.G., Leal J.F.M., Blanco-Aparicio C., Diaz-Uriarte R., Aracil M., Tercero J.C., Jimeno J., Carnero A. Levels of p27(kip1) determine Aplidin sensitivity. Mol. Cancer Ther. 6:1310-1316(2007) PubMed=19787792; DOI=10.1002/gcc.20717 Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49:40-51(2010) PubMed=20164919; DOI=10.1038/nature08768 Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R. Signatures of mutation and selection in the cancer genome. Nature 463:893-898(2010) PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458 Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 70:2158-2164(2010) PubMed=21519327; DOI=10.1038/labinvest.2011.72 Mohseny A.B., Machado I., Cai Y., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab. Invest. 91:1195-1205(2011) PubMed=22075555; DOI=10.1158/0008-5472.CAN-11-2778 Huang G., Yu L., Cooper L.J., Hollomon M., Huls H., Kleinerman E.S. Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 72:271-281(2012) PubMed=23671654; DOI=10.1371/journal.pone.0063056 Lu Y., Soong T.D., Elemento O. A novel approach for characterizing microsatellite instability in cancer cells. PLoS ONE 8:E63056-E63056(2013) PubMed=24758355; DOI=10.1186/1471-2407-14-281 Moneo V., Serelde B.G., Blanco-Aparicio C., Diaz-Uriarte R., Aviles P., Santamaria G., Tercero J.C., Cuevas C., Carnero A. Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis. BMC Cancer 14:281-281(2014) PubMed=25031706 Du L., Fan Q.-M., Tu B., Yan W., Tang T.-T. Establishment and characterization of a new highly metastatic human osteosarcoma cell line derived from Saos2. Int. J. Clin. Exp. Pathol. 7:2871-2882(2014) PubMed=26320182; DOI=10.18632/oncotarget.5177 Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S., Burkett S.S., Morrow J., Lizardo M.M., Osborne T., Li S.Q., Luu H.H., Meltzer P., Khanna C. Characterization of the metastatic phenotype of a panel of established osteosarcoma cells. Oncotarget 6:29469-29481(2015) PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074 Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J. Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression. Mol. Cancer Ther. 14:2452-2462(2015) PubMed=27397505; DOI=10.1016/j.cell.2016.06.017 Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J. A landscape of pharmacogenomic interactions in cancer. Cell 166:740-754(2016) PubMed=29334376; DOI=10.1038/nm.4475 Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A., Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A., Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A., DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P., Versteeg H.H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C. Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nat. Med. 24:176-185(2018) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019)

驗收細(xì)胞注意事項

1、收到人成骨肉瘤細(xì)胞Saos-2細(xì)胞，請查看瓶子是否有破裂，培養(yǎng)基是否漏出，是否渾濁，如有請盡快聯(lián)系。

2、收到人成骨肉瘤細(xì)胞Saos-2細(xì)胞，如包裝完好，請在顯微鏡下觀察細(xì)胞。,由于運輸過程中的問題，細(xì)胞培養(yǎng)瓶中的貼壁細(xì)胞有可能從瓶壁中脫落下來，顯微鏡下觀察會出現(xiàn)細(xì)胞懸浮的情況，出現(xiàn)此狀態(tài)時，請不要打開細(xì)胞培養(yǎng)瓶，應(yīng)立即將培養(yǎng)瓶置于細(xì)胞培養(yǎng)箱里靜止 3-5 小時左右，讓細(xì)胞先穩(wěn)定下，再于顯微鏡下觀察，此時多數(shù)細(xì)胞會重新貼附于瓶壁。如細(xì)胞仍不能貼壁，請用臺盼藍(lán)染色法鑒定細(xì)胞活力，如臺盼藍(lán)染色證實細(xì)胞活力正常請按懸浮細(xì)胞的方法處理。

3、收到人成骨肉瘤細(xì)胞Saos-2細(xì)胞后，請鏡下觀察細(xì)胞，用恰當(dāng)方式處理細(xì)胞。若懸浮的細(xì)胞較多，請離心收集細(xì)胞，接種到一個新的培養(yǎng)瓶中。棄掉原液，使用新鮮配制的培養(yǎng)基，使用進口胎牛血清。剛接到細(xì)胞，若細(xì)胞不多時血清濃度可以加到 15％去培養(yǎng)。若細(xì)胞迏到 80%左右，血清濃度還是在 10％。

4、收到人成骨肉瘤細(xì)胞Saos-2細(xì)胞時如無異常情況，請在顯微鏡下觀察細(xì)胞密度，如為貼壁細(xì)胞，未超過80%匯合度時，將培養(yǎng)瓶中培養(yǎng)基吸出，留下 5-10ML 培養(yǎng)基繼續(xù)培養(yǎng)：超過 80%匯合度時，請按細(xì)胞培養(yǎng)條件傳代培養(yǎng)。如為懸浮細(xì)胞，吸出培養(yǎng)液，1000 轉(zhuǎn)/分鐘離心 3 分鐘，吸出上清，管底細(xì)胞用新鮮培養(yǎng)基懸浮細(xì)胞后移回培養(yǎng)瓶。

5、將培養(yǎng)瓶置于 37℃培養(yǎng)箱中培養(yǎng)，蓋子微微擰松。吸出的培養(yǎng)基可以保存在滅菌過的瓶子里，存放于 4℃冰箱，以備不時之需。

6、24 小時后，人成骨肉瘤細(xì)胞Saos-2細(xì)胞形態(tài)已恢復(fù)并貼滿瓶壁，即可傳代。（貼壁細(xì)胞）將培養(yǎng)瓶里的培養(yǎng)基倒去，加 3-5ml（以能覆蓋細(xì)胞生長面為準(zhǔn)）PBS 或 Hanks’液洗滌后棄去。加 0.5-1ml 0.25%含 EDTA 的胰酶消化，消化時間以具體細(xì)胞為準(zhǔn)，一般 1-3 分鐘，不超過 5 分鐘?？梢苑?/span>入37℃培養(yǎng)箱消化。輕輕晃動瓶壁，見細(xì)胞脫落下來，加入 3-5ml 培養(yǎng)基終止消化。用移液管輕輕吹打瓶壁上的細(xì)胞，使之*脫落，然后將溶液吸入離心管內(nèi)離心，1000rpm/5min。棄上清，視細(xì)胞數(shù)量決定分瓶數(shù)，一般一傳二，如細(xì)胞量多可一傳三，有些細(xì)胞不易傳得過稀，有些生長較快的細(xì)胞則可以多傳幾瓶，以具體細(xì)胞和經(jīng)驗為準(zhǔn)。（懸浮細(xì)胞）用移液管輕輕吹打瓶壁，直接將溶液吸入離心管離心即可。